This site is intended for healthcare professionals
  • Home
  • /
  • Journals
  • /
  • Macular Degeneration
  • /
  • Levodopa Positively Affects Neovascular Age-Relate...
Journal

Levodopa Positively Affects Neovascular Age-Related Macular Degeneration

Read time: 1 mins
Published:31st Dec 2020
Author: Figueroa AG, Boyd BM, Christensen CA, Javid CG, McKay BS, Fagan TC et al.
Availability: Free full text
Ref.:Am J Med. 2021 Jan;134(1):122-128.e3.
DOI:10.1016/j.amjmed.2020.05.038
Levodopa Positively Affects Neovascular Age-Related Macular Degeneration


Background:
Age-related macular degeneration (AMD) is a common cause of blindness worldwide. Neovascular AMD (nAMD) is an advanced form of the disease, in which excess vascular endothelial growth factor (VEGF) induces growth of new blood vessels that leak fluid, accounting for 90% of vision loss in AMD. Dysfunction of the retinal pigment epithelium likely initiates AMD. Retinal pigment epithelial cells express a G protein-coupled receptor, GPR143, which downregulates VEGF in response to levodopa. Anti-VEGF therapy effectively treats nAMD, suggesting that excessive VEGF activity drives the pathology.

Methods: In an open-label pilot study, in patients with newly diagnosed nAMD and naïve to anti-VEGF injections (Cohort-1), the effects of carbidopa-levodopa on vision and anatomic outcomes were evaluated for 4 weeks. Then patients were followed 5 months further with ascending levodopa doses. Patients previously treated with anti-VEGF injection therapy (Cohort-2) were also treated with ascending levodopa doses and evaluated for 6 months.

Results: Levodopa was safe, well tolerated, and delayed anti-VEGF injection therapy while improving visual outcomes. In the first month, retinal fluid decreased by 29% (P = .02, n = 12) without anti-VEGF treatment. Through 6 months the decrease in retinal fluid was sustained, with a mean frequency of 0.38 injections/month. At month 6, mean visual acuity improved by 4.7 letters in Cohort-1 (P = .004, n = 15) and by 4.8 letters in Cohort-2 (P = .02, n = 11). Additionally, there was a 52% reduction in the need for anti-VEGF injections in Cohort-2 (P = .002).

Conclusions: Our findings suggest efficacy and support the pharmacological targeting of GPR143 with levodopa for the treatment of nAMD in future studies.


Read abstract on library site  Access full article